Craft

Corcept Therapeutics

Stock Price

$31.9

2024-06-10

Market Capitalization

$3.3 B

2024-06-10

Revenue

$482.4 M

FY, 2023

Corcept Therapeutics Summary

Company Summary

Overview
Corcept Therapeutics is a pharmaceutical company which discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome. The Company is also developing Korlym in different combinations to treat patients with triple-negative breast cancer and metastatic castration-resistant prostate cancer. In addition, it develops product candidates for the treatment of Cushing's syndrome and solid-tumor cancers.
Type
Public
Status
Active
Founded
1998
HQ
Menlo Park, CA, US | view all locations
Website
http://www.corcept.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • James N. Wilson, Chairman of the Board

    • Hazel Hunt

      Hazel Hunt, Chief Scientific Officer

    • Joseph  Belanoff

      Joseph Belanoff, Chief Executive Officer, President and Director

    • Amy Flood

      Amy Flood, Chief Human Resources, Communications Officer

    LocationsView all

    1 location detected

    • Menlo Park, CA HQ

      United States

      149 Commonwealth Dr

    Corcept Therapeutics Financials

    Summary Financials

    Revenue (Q1, 2024)
    $146.8M
    Gross profit (Q1, 2024)
    $144.3M
    Net income (Q1, 2024)
    $27.8M
    Cash (Q1, 2024)
    $149.8M
    EBIT (Q1, 2024)
    $29.5M
    Enterprise value
    $2.7B

    Footer menu